Table 2 Characteristics of colorectal neoplasias with BRAF or KRAS mutations

From: BRAF mutations and phosphorylation status of mitogen-activated protein kinases in the development of flat and depressed-type colorectal neoplasias

Sample

Location

Size (mm)

Histology

Sequence change

Codon

Amino-acid substitution

p-MAPK a

BRAF mutations

 DN

A

25

Dukes' A

1796

T → A

599

V → E

B

 FN

D

10

Adenoma

1354

C → A

452

P → T

A

 FN

T

11

Adenoma

1763

C → T

588

T → I

C

 DN

T

8

Adenoma

1354

C → A

452

P → T

A

    

1796

T → A

599

V → E

 

KRAS mutations

 PN

A

12

Adenoma

35

G → T

12

G → V

B

 PN

A

3

Adenoma

35

G → C

12

G → A

A

 PN

D

9

Adenoma

35

G → A

12

G → D

B

 PN

S

8

Adenoma

35

G → C

12

G → A

C

 PN

A

32

Adenoma

35

G → T

12

G → V

B

 PN

S

35

Adenoma

35

G → A

12

G → D

A

 PN

A

50

Adenoma

35

G → T

12

G → V

B

 PN

C

40

Dukes' A

34

G → T

12

G → C

A

 PN

R

30

Dukes' A

35

G → A

12

G → D

B

 PN

A

7

Adenoma

35

G → C

12

G → A

B

 PN

T

40

Dukes' A

35

G → A

12

G → D

A

 PN

T

12

Adenoma

35

G → A

12

G → D

B

 PN

T

30

Adenoma

35

G → A

12

G → D

B

 PN

R

35

Adenoma

38

G → A

13

G → D

B

  1. aEvaluating systems for immunohistochemical staining for p-MAPK are described in Materials and Methods. P=positive immunostaining; N=negative immunostaining; FN=flat neoplasia; DN=depressed neoplasia; PN=protruding neoplasia; R=rectum; S=sigmoid; D=descending; T=transverse; A=ascending colon; C=cecum; Dukes' A=Dukes' A carcinoma; p-MAPK=phosporylated mitogen-activated protein kinase.
Back to article page